Role of SHP2 in Colorectal Cancer Development and anti-Tumor Immunity

Tiancheng Ni

doi:10.62051/aj6djt29

Authors

Tiancheng Ni

DOI:

https://doi.org/10.62051/aj6djt29

Keywords:

SHP2; Signal pathway; Anti-tumor immunity; Colorectal cancer.

Abstract

Colorectal cancer (CRC), with the second fatality rate and the third incidence rate, is among the most prevalent malignant tumors worldwide. Therefore, it is an important task to find targeted drugs for colorectal cancer clinic therapy. Protein tyrosine phosphatase, non-receptor type 11 (PTPN11) encodes SHP2, a non-receptor tyrosine phosphatase, which is widely expressed in a variety of tissues and cells in the human body. In recent years, a number of studies have shown that SHP2 plays an important role in regulating immune cell function and colitis-related colorectal cancer progression. With the emergence of SHP2 allosteric inhibitors, SHP2 has become a promising target for the treatment of colorectal cancer patients. This article mainly discusses the structure, function, the regulatory mechanism of SHP2 in the tumor microenvironment (TME) of CRC, and the current state and prospect of SHP2 allosteric inhibitors in the therapy of CRC. With the advancement of clinical trials for various solid tumors, future research will be able to usher in more effective and safe SHP2-targeted therapies, providing more beneficial treatment options for CRC patients.

Downloads

Download data is not yet available.

References

[1] TONKS, N. K. Protein tyrosine phosphatases: from genes, to function, to disease. Nature Reviews Molecular Cell Biology, 2006, 7(11): 833-846.

[2] HOF, P., PLUSKEY, S., DHE-PAGANON, S., et al. Crystal structure of the tyrosine phosphatase SHP-2. Cell, 1998, 92(4): 441-450.

[3] LIU, Q., QU, J., ZHAO, M., et al. Targeting SHP2 as a promising strategy for cancer immunotherapy. Pharmacological Research, 2020, 152: 104595.

[4] O'KEEFE, S. J. Diet, microorganisms and their metabolites, and colon cancer. Nature Reviews Gastroenterology & Hepatology, 2016, 13(12): 691-706.

[5] SONG, Y., ZHAO, M., ZHANG, H., et al. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacology & Therapeutics, 2022, 230: 107966.

[6] PUNEKAR, S. R., VELCHETI, V., NEEL, B. G., et al. The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology, 2022, 19(10): 637-655.

[7] FEDELE, C., RAN, H., DISKIN, B., et al. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discovery, 2018, 8(10): 1237-1249.

[8] TEFFT, D., LEE, M., SMITH, S., et al. mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2002, 283(4): L700-706.

[9] CHEN, X., KELLER, S. J., HAFNER, P., et al. Tyrosine phosphatase PTPN11/SHP2 in solid tumors: bull's eye for targeted therapy?. Frontiers in Immunology, 2024, 15: 1340726.

[10] PRAHALLAD, A., HEYNEN, G. J., GERMANO, G., et al. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell Reports, 2015, 12(12): 1978-1985.

[11] GAGNé-SANSFAçON, J., COULOMBE, G., LANGLOIS, M. J., et al. SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development. Oncotarget, 2016, 7(40): 65676-65695.

[12] CHEN, Y. N., LAMARCHE, M. J., CHAN, H. M., et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature, 2016, 535(7610): 148-152.

[13] LIU, J., XIAO, Q., XIAO, J., et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduction and Targeted Therapy, 2022, 7(1): 3.

[14] ZHANG, Q., LI, Y., ZHAO, R., et al. The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/β-catenin signaling pathway. Molecular Carcinogenesis, 2018, 57(5): 619-628.

[15] XUELIANG, W., LIKUN, W., HONGQING, M., et al. SOX7 inhibits the proliferation, invasion, and migration of colorectal cancer cells by targeting the SHP-2/Wnt/β-catenin/ROS pathway. Journal of Anhui Medical University, 2024, 59(07): 1237-1243.

[16] ZENG, J., TANG, Z. H., LIU, S., et al. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World Journal of Gastroenterology, 2017, 23(10): 1780-1786.

[17] YITONG, L., YANG, S. Research progress on the regulatory mechanisms and chemical interventions in colitis-cancer transformation. Acta Pharmaceutica Sinica, 2022, 57(05): 1273-1281.

[18] XU, D., QU, C. K. Protein tyrosine phosphatases in the JAK/STAT pathway. Frontiers in Bioscience, 2008, 13: 4925-4932.

[19] HUANG, Y., WANG, J., CAO, F., et al. SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer. Scientific Reports, 2017, 7(1): 17597.

[20] CAI, P., GUO, W., YUAN, H., et al. Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer. Biomedicine & Pharmacotherapy, 2014, 68(3): 285-290.

[21] YOKOSUKA, T., TAKAMATSU, M., KOBAYASHI-IMANISHI, W., et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. Journal of Experimental Medicine, 2012, 209(6): 1201-1217.

[22] HUI, E., CHEUNG, J., ZHU, J., et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science, 2017, 355(6332): 1428-1433.

[23] HOFF, H., BRUNNER-WEINZIERL, M. C. The tyrosine phosphatase SHP-2 regulates differentiation and apoptosis of individual primary T lymphocytes. European Journal of Immunology, 2007, 37(4): 1072-1086.

[24] SHEPPARD, K. A., FITZ, L. J., LEE, J. M., et al. PD-1 inhibits T-cell receptor-induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Letters, 2004, 574(1-3): 37-41.

[25] RUDD, C. E., TAYLOR, A., SCHNEIDER, H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunological Reviews, 2009, 229(1): 12-26.

[26] CELIS-GUTIERREZ, J., BLATTMANN, P., ZHAI, Y., et al. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell Reports, 2019, 27(11): 3315-3330.e7.

[27] LIU, W., GUO, W., SHEN, L., et al. T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice. Oncotarget, 2017, 8(5): 7586-7597.

[28] CASSETTA, L., POLLARD, J. W. Targeting macrophages: therapeutic approaches in cancer. Nature Reviews Drug Discovery, 2018, 17(12): 887-904.

[29] ACHKOVA, D., MAHER, J. Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer. Biochemical Society Transactions, 2016, 44(2): 333-341.

[30] ORONSKY, B., CARTER, C., REID, T., et al. Just eat it: A review of CD47 and SIRP-α antagonism. Seminars in Oncology, 2020, 47(2-3): 117-124.

[31] BARKAL, A. A., BREWER, R. E., MARKOVIC, M., et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature, 2019, 572(7769): 392-396.

[32] XIAO, P., ZHANG, H., ZHANG, Y., et al. Phosphatase Shp2 exacerbates intestinal inflammation by disrupting macrophage responsiveness to interleukin-10. Journal of Experimental Medicine, 2019, 216(2): 337-349.

[33] GAO, J., WU, W., QU, P., et al. SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade. Acta Pharmaceutica Sinica B, 2021, 11(5): 1235-1248.

[34] ZHAO M, GUO W, WU Y, et al. SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade. Acta Pharmaceutica Sinica B, 2019, 9(2): 304-315.

[35] FAN Hao. Study on the synergistic lethality of combined blockade of WWP1 and SHP2 in colorectal cancer and its mechanism. Naval Medical University, 2024. DOI: 10.26998/d.cnki.gjuyu.2024.000052.

[36] LAROCHELLE J R, FODOR M, VEMULAPALLI V, et al. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. Nature Communications, 2018, 9(1): 4508.